Preclinical evidence suggests that short-term fasting and diets that mimic fasting can protect healthy cells against chemotherapy, while simultaneously rendering cancer cells more vulnerable to the treatment. However, clinical research evaluating the potential of short-term fasting in patients with cancer is still in its infancy.

This was shown in a new paper published last week in Nature: Communications by Dutch scientists from Leiden who looked at fasting-mimicking diets in patients undergoing chemotherapy for the most common form of breast cancer.

In the trial conducted by Dr. Judith Kroep and colleagues, 129 patients with HER2-negative stage II/III breast cancer followed either a fasting-mimicking diet or their regular diet for 3 days prior to and during neoadjuvant chemotherapy (treatment given as a first step to shrink a tumor before surgery).